In a prospective, multicenter, double-blind study, the interval to clinical relapse in patients with acute bacterial exacerbations of chronic bronchitis from whom a pretherapy pathogen was isolated was compared following treatment with ciprofloxacin or cefuroxime axetil. Clinical and microbiological responses at the end of therapy were secondary efficacy variables. Outpatients randomly received either ciprofloxacin or cefuroxime axetil (500 mg twice a day for 14 days). Three hundred seven patients with acute exacerbations of chronic bronchitis were enrolled, of whom 208 had an exacerbation due to a bacterial pathogen. Clinical resolution at the end of ciprofloxacin and cefuroxime axetil therapy for patients for whom efficacy could be evaluated was 93% and 90%, respectively. Bacteriologic eradication rates were statistically higher for ciprofloxacin recipients (96% [89 of 93]) than for cefuroxime axetil recipients (82% [80 of 97]) (P õ .01). The median infection-free interval was 146 days for ciprofloxacin recipients vs. 178 days for cefuroxime axetil recipients (P Å .37). In conclusion, ciprofloxacin was associated with an infection-free interval and clinical response that were similar to those associated with cefuroxime axetil, but the bacteriologic eradication rate associated with ciprofloxacin was statistically significantly higher than that associated with cefuroxime axetil.
Approximately 4% to 21% of adults residing in the United Ç50% of patients for whom a bacterial etiology is proven or highly suspected. Although AECB in some patients resolve States have symptoms of chronic bronchitis, with acute infectious exacerbations being the most common precipitating factor without antimicrobial therapy, there is a need to identify effecleading to hospitalization [1] . Acute exacerbations of chronic tive therapeutic modalities that reduce the morbidity (e.g., probronchitis (AECB) are characterized principally by increased longed respiratory insufficiency and development of pneumocough, increased sputum production, and altered appearance nia) due to ABECB [4 -6] . Prompt recognition of symptoms of sputum [2] . The pathogens most commonly associated with and signs of an acute bacterial exacerbation and early initiation acute bacterial exacerbations of chronic bronchitis (ABECB) of effective therapy can have a positive effect (i.e., decrease include Haemophilus influenzae, Moraxella catarrhalis, and the number of acute episodes and lengthen the time between Streptococcus pneumoniae [2, 3] . Other less common etiologies episodes). The choice of an appropriate antimicrobial for treat-(õ6%) include Haemophilus parainfluenzae, Klebsiella pneument of ABECB is complicated by the increasing problems of moniae, and Pseudomonas aeruginosa [3] .
resistance, including penicillin-resistant pneumococci [7] and The selection of antibacterial therapy for AECB remains b-lactamase-producing M. catarrhalis and H. influenzae [8] . controversial because most investigations do not identify the Many previously reported studies of AECB suffered from design flaws, including nonspecific criteria for study entry, absence of gram staining, lack of bacterial etiology, deficient criteria for outcome analysis, varying degrees of illness sever- tions, a recent meta-analysis demonstrated a small degree of Informed consent was obtained from the patients, their parents, or their benefit in favor of antimicrobials vs. placebo as treatment of guardians, and the guidelines for human experimentation of the U.S. Department of Health and Human Services were followed in the conduct of this AECB [9] . Several well-designed studies limited to ABECB study.
reported that ampicillin, amoxicillin, doxycycline, and trimethThe views expressed in this article do not necessarily represent the views oprim-sulfamethoxazole were associated with relatively low of the Department of Veterans Affairs of the U.S. Government.
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were varied [10 -16] ; oral cephalosporins, such as cefaclor and Study Design and Antimicrobial Therapy of ciprofloxacin (750 mg twice daily) were found to be associated with end-of-therapy clinical cure rates, clearance of bacteThis was a prospective, multicenter, randomized, doubleria by gram-staining criteria, and infection-free intervals similar blind, comparative study. Both study drugs were encapsulated to those associated with ampicillin [15] . Several other studies in no. 000, opaque, gelatin capsules for blinding purposes. in which lower doses were used supported these findings [17 -Ciprofloxacin (Cipro, Bayer Corporation, Pharmaceutical Divi-22]. Additional studies found that cefuroxime axetil was at sion, West Haven, CT) and cefuroxime axetil (Ceftin, Allen & least as effective as cefaclor in the treatment of AECB or acute Hanburys, Research Triangle Park, NC) were supplied as bronchitis [26, 27] . 500-mg tablets. All patients received one capsule twice daily The present study was designed primarily to compare the for 14 days. Patients were advised to take study medication length of the infection-free interval between an ABECB and with the morning and evening meals. Concomitant antibacterial the next exacerbation following treatment with ciprofloxacin agents were not allowed during the study period. Use of bronor cefuroxime axetil. In addition, secondary objectives included chodilators, mucolytics, or expectorants was permitted during comparisons of clinical, bacteriologic, and safety responses the study period. between the two antimicrobials.
Antimicrobial effectiveness was evaluated by means of clinical determinations (e.g., physical examination and history with an emphasis on respiratory signs and symptoms) and laboratory determinations (including cultures of pretreatment and postPatients and Methods treatment sputum samples and gram staining of sputum obtained at 2, 6, 12, 24, and 36 weeks after therapy or when a Hospitalized or outpatient adults 18 years of age or older treatment failure or a new AECB occurred). Viral, mycoplasfor whom AECB was the primary diagnosis were enrolled in mal, and chlamydial cultures or serologies were not performed the study from 17 centers. Eligible males or females who had as part of this study. Susceptibility of all isolated pathogens chronic bronchitis with underlying chronic obstructive pulmowas determined by using procedures of the National Committee nary disease (COPD), chronic bronchial asthma, or both as for Clinical Laboratory Standards [29] . Patients from whom defined by the American Thoracic Society [28] and who had resistant pathogens were isolated were not removed from the an acute exacerbation of bronchitis clinically attributable to study. a bacterial pathogen were eligible for study enrollment. As Two populations were evaluated in this study: patients for determined by a pretherapy medical history and physical examwhom drug efficacy could be evaluated (efficacy-valid populaination, patients had to have increases in some clinical bronchotion; see below) and all randomized patients receiving study pulmonary symptoms (including increased cough, sputum promedication (intent-to-treat population). duction, or chest congestion), purulent changes in the sputum, and/or presence of fever or laboratory evidence of infection (i.e., increased WBC count). In addition, gram staining of a Efficacy Evaluation sputum smear had to reveal õ10 squamous epithelial cells, ú25 leukocytes per low-power field, and a likely bacterial For a course of therapy to be judged evaluable for drug pathogen in increased numbers (e.g., Haemophilus-like efficacy, the following criteria had to be satisfied: (1) acute organisms, §12 morphological types per oil immersion field; respiratory tract infection confirmed by the presence of signs pneumococcus-like organisms, §8 morphological types per oil and symptoms of infection; (2) gram staining and cultures of immersion field; M. catarrhalis -like organisms, §18 morphosputum specimens obtained before therapy that revealed a baclogical types per oil immersion field; or gram-negative bacilli, terial pathogen; (3) performance of cultures of sputum samples §2 morphological types per oil immersion field).
obtained at designated times after therapy; (4) administration Patients with any of the following characteristics were exof the study drug for a minimum of 12 full days, unless treatcluded from the study: evidence of a severe respiratory tract ment was a failure or was prematurely discontinued because of infection and parenteral antimicrobial therapy or mechanical an adverse event; (5) no other antimicrobial agent administered ventilatory support; evidence of lobar consolidation on a chest concomitantly with the study drug; and (6) patient available roentgenogram; recent diagnosis or unresolved lung or chest for 9 months of follow-up or until the occurrence of the next cavity malignancy; need for concomitant treatment with antimi-AECB. crobial agents with a spectrum of activity similar to that of The primary measure of efficacy was the length of the infeceither study drug; allergy to carboxyquinolones or b-lactam tion-free interval. Failures during therapy were counted as zero agents; administration of another investigational drug within infection-free days. For patients who had intervals during 30 days of study enrollment; previous enrollment in this study; which no clinical relapse or new infection occurred in the 36-pregnancy or nursing; or a baseline serum creatinine level of week observation period after therapy, the interval was as- §3.0 mg/dL. Written informed consent was obtained from each signed the number of days to the last time for which information was known; therefore, the exact length of the infection-free patient before study enrollment. bution of times to failure. The estimated survival function was plotted over time for each group of study drug recipients. The The following parameters of clinical response were based on results of serial examinations of the patients: change in survival curves for each group of study drug recipients were compared by using a Wilcoxon rank test (which places more cough frequency and severity; sputum characteristics (thickness and volume); auscultatory findings (rales, rhonchi, wheezing, weight on early times to failure) and the logrank test (which places more weight on later times to failure). and breath sounds); dyspnea; chest pain or discomfort; friction rub; prolongation of expiratory phase; temperature of ú38ЊC;
To test the comparability of the treatment groups, categorical variables (including demographic and clinical characteristics) and WBC count of ú12,000/mm 3 . The clinical response at the end of therapy was defined as resolution or failure. Resolution were analyzed by using the Cochran-Mantel-Haenzel test, adjusting for the multicenter nature of the trial, or the x 2 test. was the disappearance of both acute clinical symptoms and signs (complete return to a stable preexacerbation condition of For continuous variables, an analysis of variance model was fitted with treatment group, center, and treatment by center chronic bronchitis) or sufficient improvement in the patient's condition such that additional antimicrobial treatment was not interaction as factors. The incidence rates of adverse events were compared between the two treatment groups by using the necessary. At the follow-up evaluations (2, 6, 12, 24, and 36 weeks or at the time of the next AECB), the patient's clinical
For the end of therapy and follow-up evaluation clinical and response was determined to be either continued resolution or clinical relapse by using similar criteria. The clinical response bacteriologic responses, two-sided 95% confidence intervals were calculated for the differences between resolution and was considered indeterminate if insufficient data were available or if the patient's response was confounded by other medical eradication rates (ciprofloxacin minus cefuroxime axetil); a Cochran-Mantel-Haenzel weighting method was used to adconditions or concomitant medication.
The bacteriologic response, which was determined at the end just for the multicenter nature of the trial. The two treatments were declared equivalent at the 2.5% significance level if the of therapy, was defined as eradication, presumed eradication (no culture material from a patient for whom therapy was lower 95% confidence limit was §00.10. These analyses were performed for both the efficacy-valid and intent-to-treat categorized as a clinical success), or persistence. In addition, superinfection was defined as a clinical failure in the presence populations. of a repeated sputum culture identifying a causative organism different from the pretherapy isolate that required alternate Results antimicrobial therapy. Bacteriologic responses at the follow-up evaluation included continued eradication, continued presumed Study Population eradication, relapse (original causative organism present), and reinfection (new causative organism identified). The bacterio-A total of 307 adults with AECB (155 ciprofloxacin recipients and 152 cefuroxime axetil recipients) were enrolled in the logic response was considered indeterminate if the pretherapy culture was negative, if a culture was not performed for a study at 17 clinical sites; all 307 were included in the intentto-treat population. Drug efficacy could be evaluated for 208 patient with a clinical response of failure, or if the response was confounded by concomitant antimicrobial therapy.
patients (68%; 103 ciprofloxacin recipients and 105 cefuroxime axetil recipients [efficacy-valid population]). Ninety-nine paAll patients receiving the study drug for any time were evaluated for drug safety (intent-to-treat population). Blinded investients (52 ciprofloxacin recipients and 47 cefuroxime axetil recipients) were excluded from analysis of the efficacy-valid tigators rated adverse events according to their severity (mild, moderate, severe, or serious or life threatening) and their relapopulation primarily because no pretherapy pathogen was isolated (23 patients) and the duration of treatment was inadequate tionship to the study drug (probable, possible, remote, or none).
(26 patients). Reasons for premature discontinuation of study drug therapy were similar between the treatment groups. The baseline demographics and clinical characteristics of
Statistical Analysis
the efficacy-valid population were similar between the two treatment groups (table 1) . Most patients in each treatment The primary goal of this study was to demonstrate the superiority of ciprofloxacin over cefuroxime axetil with respect to group had underlying COPD (less than three exacerbations in the past 12 months that required antibiotic intervention); most duration of the infection-free interval. The secondary measures of efficacy were clinical and bacteriologic responses at the end enrolled patients were not hospitalized for their current exacerbation. There was a statistically significant difference beof therapy. With the sample size of patients enrolled, the study had a power of ú80% to detect a difference between citween study drug groups regarding general health; 73% of cefuroxime axetil recipients were in good to excellent health profloxacin and cefuroxime axetil, assuming a ratio of 175 days to 100 days in the true time to relapse [30] .
compared with only 56% of ciprofloxacin recipients (P £ / 9C57$$oc02 09-15-98 16:50:49 cida UC: CID .05). Baseline demographic and clinical characteristics of the cefuroxime axetil recipients, three had eradication or presumed eradication, and seven had known persistence. The remainder intent-to-treat population were similar to those of the efficacyvalid population.
of patients with clinical failures in both treatment groups had indeterminate bacteriologic responses. During the 36-week folThe use of therapeutic procedures and/or adjuncts (i.e., oxygen, nebulizer, and respiratory therapy) was similar during the low-up period, clinical relapse or new infection was described in 50 ciprofloxacin recipients (53%) and 41 cefuroxime axetil study for the two treatment groups (17% of ciprofloxacin recipients and 14% of cefuroxime axetil recipients). Four patients in recipients (44%) (95% CI, 00.23 -0.05). the efficacy-valid population (two per study drug group) received concomitant antimicrobial agents: one ciprofloxacin reBacteriologic Response cipient and one cefuroxime axetil recipient developed diarrhea due to Clostridium difficile and were treated with oral vancomyBacteriologic eradication at the end of therapy, including cin and metronidazole, respectively; one cefuroxime axetil represumed eradication, was statistically significantly different cipient was also treated with topical mupirocin for wound lacerbetween ciprofloxacin recipients (96%) and cefuroxime axetil ations, and one ciprofloxacin recipient received intravenous recipients (82%) (P õ .01; 95% CI, 0.046 -0.215) (figure 1). cefuroxime therapy for pneumonia following resolution of the In addition, three ciprofloxacin recipients had superinfections AECB at an unknown time after therapy.
(i.e., a symptomatic episode requiring alternative antimicrobial therapy) due to five organisms (Acinetobacter lwoffii, Acinetobacter baumannii, Stenotrophomonas maltophilia, b-lacta-
Clinical Response
mase-negative H. parainfluenzae, and S. pneumoniae). Two cefuroxime axetil recipients had superinfections caused by four In the efficacy-valid population, clinical resolution at the end of therapy was reported for 93% of ciprofloxacin recipients different organisms (two strains of Escherichia coli, Klebsiella oxytoca, and P. aeruginosa). Sixty-four percent of ciprofloxaand 90% of cefuroxime axetil recipients (95% CI, 00.048 -0.104; P Å .47) (figure 1). Seven ciprofloxacin recipients and cin recipients and 65% of cefuroxime axetil recipients had continued and/or presumed eradication at the follow-up evalua-10 cefuroxime axetil recipients had clinical failures. Of the seven ciprofloxacin recipients, five had a bacteriologic response tion (time of clinical relapse or last follow-up). Bacteriologic response data (i.e., relapse and reinfection) during the 36-week of eradication, and one had documented persistence. Of the 10 / 9C57$$oc02 09-15-98 16:50:49 cida UC: CID 1 (P. aeruginosa) resistant to both study drugs. Eleven of these pathogens were isolated from patients in the efficacy-valid population (one ciprofloxacin recipient and 10 cefuroxime axetil recipients). A resistant S. pneumoniae isolate was recovered from one ciprofloxacin recipient who had clinical resolution and bacteriologic eradication at the end of therapy. Two cefuroxime axetil recipients from whom resistant pathogens were isolated at baseline (two Pseudomonas isolates and one Serratia isolate) had clinical failures. Pretherapy and follow-up susceptibility information was available for 26 (five persisting and 21 recurring) pathogens from 23 ciprofloxacin recipients. No changes in susceptibility to either drug were reported for the five persisting pathogens. Six changes were found for the 21 recurring pathogens: two S. pneumoniae isolates went from susceptible to intermediately resistant to ciprofloxacin, and four H. influenzae isolates went from susceptible to either intermediately resistant (three) or resistant (one) to cefuroxime axetil. Pretherapy and follow-up susceptibility data were available for 31 (19 persisting and 12 recurring) organisms from 28 cefuroxime axetil recipients. Two changes were found for the 19 Fifty ciprofloxacin recipients (32%) and 55 cefuroxime axetil recipients (36%) had at least one adverse event considered to be at least remotely drug-related. Diarrhea, nausea, headache, and dizziness were the most common events ( §4% occurrence) reported in both treatment groups. Most adverse events were mild to moderate in severity (82% in ciprofloxacin recipients and 82% in cefuroxime axetil recipients) and decreased or resolved with sufficient follow-up. Study drug use was prematurely discontinued because of one or more adverse events in 11 ciprofloxacin recipients and seven cefuroxime axetil recipients.
Discussion
In this study of adults with ABECB, ciprofloxacin was associated with an infection-free interval and clinical response similar to those associated with cefuroxime axetil, but the bacteriologic eradication rate associated with ciprofloxacin was statistically significantly higher than that associated with cefur- xime axetil recipients. One limitation of the current study was the lack of objective pulmonary function measurements (forced expiratory volume in 1 second and forced vital capacity), alsusceptible to intermediately resistant to cefuroxime axetil, though some experts suggest that possible changes in lung and one H. influenzae isolate went from susceptible to resisfunction may be too small to detect differences between comtant to cefuroxime axetil. Only one change was noted for parative regimens. As such, measures of changes in a patient's the 12 recurring pathogens: an Enterobacter cloacae isolate pulmonary status by study drug in the current trial relied on went from susceptible to intermediately resistant to cefurosubjective clinical assessment. xime axetil. No changes in susceptibility to ciprofloxacin Unlike many other previous studies, this trial provided supwere reported in this subgroup.
portive evidence of bacterial infection by gram staining in addition to bacterial cultures. In a previous study [31] , gram staining
Infection-Free Interval
demonstrated high levels of bacteria during acute exacerbations In the efficacy-valid population, the estimated median infecin 100% of 213 cases, whereas it was positive only in 5% tion-free interval was 146 days for ciprofloxacin recipients vs.
of 130 cases during stable periods. Our study confirmed that 178 days for cefuroxime axetil recipients (P Å .37) (figure H. influenzae (25%) and M. catarrhalis (21%) were the most 2). Fifty-one percent of ciprofloxacin recipients and 61% of common pathogens; S. pneumoniae (10%) was the third most cefuroxime axetil recipients did not have a relapse during the common pathogen. Notably, the overall bacteriologic eradica-36-week period after therapy. tion rate was substantially higher for ciprofloxacin recipients Because the general health status differed between the two (96%) than for cefuroxime axetil recipients (82%). Regardless treatment groups at study entry, this variable was tested as a of previous concerns, only one (10%) of 10 pneumococcal covariate; overall it was not found to be associated with the organisms failed to be eradicated following ciprofloxacin therinfection-free interval (P ú .26). In the subset of patients with apy. Furthermore, one-half of the persistent organisms from a good to excellent health status at study entry, the median cefuroxime axetil recipients were common pathogens (i.e., infection-free interval was 147 days for ciprofloxacin recipients H. influenzae and M. catarrhalis). Although ciprofloxacin was and 194 days for cefuroxime axetil recipients. However, analyassociated with a bacteriologic eradication rate higher than that sis of the subset of patients with a fair to poor health status at associated with cefuroxime axetil, this finding did not translate study entry revealed a median infection-free interval of 139 into a longer infection-free interval, thereby suggesting that days for ciprofloxacin recipients and 108 days for cefuroxime causes other than bacterial pathogens (e.g., environmental axetil recipients.
and/or comorbidity factors) were responsible for initiating the study end point AECB.
Safety and Adverse Events
Despite the original hypothesis that ciprofloxacin recipients would have a longer infection-free interval, the estimated surSeventy-six ciprofloxacin recipients (49%) and 85 cefuroxime axetil recipients (56%) reported at least one treatmentvival curves were not statistically different between the two / 9C57$$oc02 09-15-98 16:50:49 cida UC: CID study drug groups. One possibility for this unexpected finding reported much lower values (64 to 112 days for ciprofloxacin recipients and 82 to 147 days for cefuroxime axetil recipients). may lie in the fact that a significantly greater proportion of cefuroxime axetil recipients (73%) than of ciprofloxacin recipiThis large variation may be explained by the fact that the first study site is a specialized center for the management of AECB. ents (56%) had excellent or good health at study enrollment. A subanalysis of cefuroxime axetil recipients revealed that the Patients with recurrence of lower respiratory tract infection at this center were evaluated completely for the possibility of infection-free interval increased to 194 days for patients with excellent or good health compared with only 108 days for nonbacterial etiologies of AECB. As such, many patients at this center were not labeled as having a repeated bacterial patients with fair or poor health. For ciprofloxacin recipients, excellent or good health was associated with an infection-free infection but instead were managed with oral steroids and/or supportive therapy with a high rate of success. interval of 147 days compared with 139 days for patients with fair or poor health. Further subanalyses were conducted that This investigation demonstrates that ciprofloxacin is an effective empirical agent for the management of ABECB. Cistratified patients by the presence of asthma and COPD. For ciprofloxacin recipients, the results were similar (median infecprofloxacin compared favorably with cefuroxime axetil in terms of clinical efficacy, including infection-free intervals; tion-free interval of 134 days for patients with asthma and 147 days for patients with COPD). However, for cefuroxime axetil however, the bacteriologic eradication rate associated with ciprofloxacin was statistically significantly higher than that assorecipients, the infection-free interval varied greatly (median infection-free interval of 112 days for patients with asthma and ciated with cefuroxime axetil. Controlled trials of higher doses of ciprofloxacin for the management of bacteriologically con-255 days for patients with COPD).
One limitation of the study is the lack of information on firmed acute infectious exacerbations in large patient populations are warranted to determine if the time to the next relapse smoking history, a factor that also may have contributed to the differences in the infection-free interval. Further studies need can be extended. to collect information on smoking history since smoking is associated with an increased risk of infection. In addition, the The expected duration of the infection-free interval for ciprincipal investigator, Dennis A. Ruff, MD; and study coordinator, profloxacin recipients was based primarily on data from a preJanice E. Pierce, RN (South Texas Clinical Trials, San Antonio, viously reported study [15] . This study used a higher dosage TX); principal investigator, Marvin J. Bittner, MD; and study coorof ciprofloxacin (750 mg twice daily) than the current study; 
